Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

ZBIO Zenas BioPharma, Inc. Common Stock
$19.59 0.00% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy ZBIO stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 1.1B
Enterprise value 830.7M
Trailing PE 1.4345282
Forward PE -4.9771576
PEG Ratio -0.018950872536842
Enterprise to EBITDA -4.247
Enterprise to revenue 55.382
Price to book MRQ 4.2144856
Price to sales TTM 70.17657

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 15.0M
EBITDA -195616992
Diluted EPS TTM 13.67
Total Cash (MRQ) 290.9M
Current ratio (MRQ) 5.659
Operating Cash Flow (TTM) -158472992

ZBIO trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent ZBIO News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.